Home/Pipeline/Antifibrotic Therapy Program

Antifibrotic Therapy Program

Breast Cancer

Pre-clinicalActive

Key Facts

Indication

Breast Cancer

Phase

Pre-clinical

Status

Active

Company

MeCo Diagnostics

About MeCo Diagnostics

MeCo Diagnostics is a private, early-stage biotech founded in 2018 and based in San Diego, operating in the diagnostics and therapeutics intersection. The company is developing an antifibrotic therapy platform, with an initial focus on breast cancer, emphasizing patient stratification through a 'good fit' diagnostic approach. It is currently in a pre-clinical or discovery stage, positioning itself to address the significant unmet need in cancer-associated fibrosis. The company is likely pre-revenue and reliant on private investment to advance its platform.

View full company profile

Therapeutic Areas

Oncology Fibrosis

Other Breast Cancer Drugs

Drug	Company	Phase	Status
inPROBE for HER2	SDS Optic	Clinical Investigation	Completed (March 2023)
ACT‑BC1	Anthrocell	Preclinical	Active
APA-1000 Breast Thermotherapy System	Medifocus	Phase III	Pivotal Trial Approved (IDE/ITA)
Early‑Detection Breast Cancer Screening	Karkinos Healthcare	Market	Active
Unnamed Breast Cancer Program	Click Therapeutics	Pilot/Phase 2	Active
Lerociclib (Lerocliclib)	Chemogenics BioPharma	Phase 3	Completed Phase 3, awaiting FDA approval
AT-017	Asieris Pharmaceuticals	Not Specified	Active
CDK2 inhibitor	Acellera	Pre-clinical	Hit Identification
NP-G2-044	Novita Pharmaceuticals	Phase 2a	Active (subset)
Maveropepimut-S (MVP-S)	BioVaxys	Clinical Evaluation	Active
Cannabics® BRST-33	CNBX Pharmaceuticals	Discovery	In vitro POC
Undisclosed	Biossil	Phase 2/3	Active